INTRODUCTION
============

Thrombotic microangiopathy (TMA) encompasses severe conditions caused by microvascular thrombosis including thrombotic thrombocytopenic purpura (TTP) and Shiga toxin-mediated hemolytic uremic syndrome (HUS).[@b1-13-46] These disorders, associated with high morbidity, share unifying features: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ disfunction.[@b2-13-46] MAHA describes Coombs-negative hemolysis from intravascular red blood cell fragmentation producing schistocytes on peripheral blood smear.[@b3-13-46] TTP and HUS are not the only forms of TMA. Cases of metabolism mediated TMA from vitamin B12 deficiency have been reported termed pseudothrombotic microangiopathy (pseudo-TMA).[@b4-13-46]--[@b6-13-46] Differentiating the etiology of TMA, specifically TTP and vitamin B12 deficiency is critical as the treatments and prognoses are different. Treatment for TTP requires plasma exchange associated with increased complications and cost as compared to the treatment for vitamin B12 deficiency, which is simply supplementation.[@b7-13-46] Unnecessary plasma exchange has been reported due to the misdiagnosis of TTP when the actual diagnosis was vitamin B12 deficiency.[@b8-13-46]

The incidence of TTP is less than one case per year per million.[@b9-13-46] Vitamin B12 deficiency, on the other hand, is far more common. The most frequent serum vitamin B12 cut-off level to diagnose vitamin B12 deficiency is 150 pmol/L (203 pg/ml). Using this serum vitamin B12 cut-off level, the prevalence of vitamin B12 deficiency is 5% to 15%.[@b10-13-46] Approximately 2.5% of vitamin B12 deficiency cases present with hemolytic anemia, thrombocytopenia, and schistocytosis.[@b11-13-46] Therefore, even though a small proportion of vitamin B12 presents with MAHA, the incidence is higher than TTP. We report a case of a man presenting with profound pancytopenia concerning for TTP that was actually secondary to vitamin B12 deficiency.

CASE REPORT
===========

A 65-year-old Caucasian male with a history of hepatitis C presented to the emergency room after laboratory evaluation at his primary care provider's office revealed pancytopenia. He endorsed a one-month history of increasing fatigue, interfering with his work as a security guard. He denied a history of blood or coagulation disorders, autoimmune disease, cancer, recent trauma, immobilization, or travel. He initially denied any history of heavy alcohol consumption.

Vital signs were within normal limits. On physical exam, conjunctival pallor was noted. Cardiovascular exam was significant for a 2/6 systolic murmur. He had bilateral 1+ pitting edema of the lower extremities to the mid-calf with discoloration consistent with venous stasis. His skin showed diffuse ecchymosis of the forearms bilaterally. [Table 1](#t1-13-46){ref-type="table"} shows lab values on admission.

A peripheral blood smear showed 4% schistocytes, 2+ teardrop cells, and hypersegmented neutrophils. Coomb's test was negative. His iron studies and folate levels were within normal limits. Coagulation studies were within normal limits. The patient was transfused with packed red blood cells. A diagnosis of vitamin B12 deficiency was made and treatment with intramuscular vitamin B12 initiated. After further questioning, he disclosed that his diet consisted almost exclusively of tomato soup and meatless sandwiches. Since the death of his father and brother earlier in the year, he had increased his alcohol consumption significantly more than he initially indicated, drinking around 8 -- 10 beers daily. His ADAMTS13 activity later returned as 100% activity. He was treated with intramuscular vitamin B12 and follow-up as an outpatient showed complete resolution of his anemia four months later.

DISCUSSION
==========

Patients showing schistocytosis and thrombocytopenia merit screening for TTP as this disease can be lethal. The PLASMIC score ([Table 2](#t2-13-46){ref-type="table"}) quantifies the likelihood of TTP.[@b12-13-46] Each criterion scores a point. If the score is in the intermediate to high range (5 to 7 points), a presumptive diagnosis in the appropriate clinical context can be made and is sufficient to initiate treatment. Our patient's PLASMIC score of 5 fell into the intermediate risk. However, his clinical presentation was due solely to vitamin B12 deficiency. Differentiating vitamin B12 deficiency with pseudo-TMA from TTP is of the utmost importance to avoid unnecessary plasma exchange. As with TTP, vitamin B12 deficiency also can present with MAHA and thrombocytopenia, as seen in our case.

Vitamin B12 is necessary for the proper synthesis of deoxyribo-nucleic acid (DNA) and cell division of hematopoietic cells.[@b13-13-46] Without adequate stores the nucleated precursors of hematopoietic cells, lines cannot mature, leading to megaloblastic anemia. Neutropenia and thrombocytopenia subsequently may develop.[@b14-13-46] As the precursor cells are unable to mature, cellular arrest occurs, leading to intramedullary cell death. Lactate dehydrogenase (LDH) enzymes are released during the destruction of nucleated red cells. Therefore, intramedullary hemolysis of immature red blood cells, as seen in vitamin B12 deficiency, can lead to high LDH levels. In fact, LDH levels may be useful in differentiating TTP from vitamin B12 deficiency, as most patients with TTP exhibit LDH levels less than 2500 IU/L, while levels exceeding 2500 IU/L indicate the possibility of vitamin B12 deficiency.[@b15-13-46]

As bilirubin elevation results from the catabolism of heme, the hemolysis of erythroid precursors, which produce little hemoglobin, results in only a minor increase in bilirubin levels.[@b16-13-46] In contrast, peripheral hemolysis of mature erythrocytes, which have a high amount of hemoglobin, leads to a much higher indirect bilirubin level. Our patient's LDH levels were much higher relative to his bilirubin levels, more consistent with intramedullary hemolysis of immature erythrocytes secondary to vitamin B12 deficiency.

ADAMTS13 cleaves von Willebrand factor multimers that are secreted from vascular endothelial cells.[@b17-13-46] ADAMTS13 deficiency results in unusually large von Willebrand factor multimers, causing platelet thrombi in small vessels with high shear rates, creating schistocytes. Vitamin B12 causes hyperhomocysteinemia, decreased plasma methionine levels, and methylmalonic aciduria. These are associated with platelet activation, generation of reactive oxygen species, endothelial dysfunction, increased tissue factor expression, and coagulation activation. The combination of these factors is thought to lead to peripheral hemolysis, causing schistocytes. Individuals with homozygous or compound heterozygous mutations in a gene encoding the methylmalonic aciduria and homocystinuria type C protein (MMACHC) are more predisposed to pseudo-TMA as compared to vitamin B12 deficiency without MAHA.

The most helpful parameter in differentiating pseudo-TMA and TTP may be the reticulocyte count.[@b15-13-46] Those who have pseudo-TMA averaged a 3% reticulocyte count and TTP averaged 18%.[@b18-13-46] Our patient's level of 3.8% was more consistent with vitamin B12 deficiency. The reticulocyte production index (RPI) makes corrections for both the hematocrit and the reticulocyte lifespan.[@b19-13-46] Making these corrections determines whether the reticulocytosis truly is increased. In cases of anemia, RPI less than 2 is considered inappropriately low. Our patient's RI was 0.50, indicating a hypoproliferative process.

Both TMA and vitamin B12 deficiency can present with a high MCV.[@b20-13-46] In the setting of hemolytic disorders, a high MCV can be due to a high reticulocyte count. Severe macrocytosis with levels greater than 115 fL is associated almost exclusively with megaloblastic anemias, including vitamin B12 deficiency. Our patient's high MCV with a low RI is more consistent with megaloblastic anemia rather than TTP. Of note, ADAMTS13 activity level typically is decreased in TTP; however, due to time limitations, treatment decisions often are initiated prior to obtaining it.

CONCLUSION
==========

In summary, vitamin B12 deficiency associated with pseudo-TMA can present similarly to TTP with hemolytic anemia, schistocytosis, and thrombocytopenia. Obtaining the correct diagnosis is possible if the clinician understands the clinical differences and differing mechanisms. Vitamin B12 deficiency typically presents with an elevated MCV and relatively low reticulocyte count, whereas TTP may or may not present with an elevated MCV and elevated reticulocyte count.[@b18-13-46],[@b20-13-46] MCV greater than 115 fL is consistent with megaloblastic anemias. Vitamin B12 deficiency typically presents with relatively higher levels of LDH and lower levels of bilirubin compared with TMA.[@b15-13-46],[@b16-13-46] MAHA is a feature of both TMA and pseudo-TTP, however, the etiologies of the two differ.[@b17-13-46]

###### 

Lab values on admission.

  Lab                       Value          Reference Range
  ------------------------- -------------- -----------------
  WBC                       1.6 K/cmm      3.60 -- 11.20
  Hemoglobin                4.8 g/dl       13.1 -- 16.8
  Hematocrit                15.0%          38.2 -- 48.4
  Platelet count            34 K/cm        150 -- 400
  Mean corpuscular volume   121.3 fL       80.1 -- 98.5
  Reticulocyte count        3.8%           0.50 -- 2.3
  Reticulocyte count, ABS   0.046 M/ul     0.022 -- 0.101
  Total bilirubin           1.6 mg/dL      0.2 -- 1.2
  Direct bilirubin          0.7 U/L        0.0 -- 0.5
  Lactate dehydrogenase     3449 Units/L   125 -- 243
  Creatinine                0.76 mg/dL     0.7 -- 1.3
  Haptoglobin               \< 8 mg/dL     44 -- 215
  Vitamin B12               66 pg/mL       213 -- 816
  Parietal cell antibody    62.5 Unit      ≤ 20.0
  Intrinsic factor Ab       Negative       Negative

###### 

PLASMIC score template.

  --------------------------------------------------------------------------------------------------------------------------------------------
  PLASMIC Indications (1 point for each indication)
  Platelet count \< 30,000/microL
  One or more indicators of hemolysis: Reticulocyte count (percentage \> 2.5% or haptoglobin undetectable or indirect bilirubin \> 2.0 mg/dL
  No active cancer in the preceding year
  No history of solid organ or hematopoietic stem cell transplant
  Mean corpuscular volume (MCV) \< 90 femtoliters
  International normalized ratio (INR) \< 1.5
  Creatinine \< 2.0 mg/dL
  PLASMIC score: Risk of severe ADAMTS13 deficiency
  0 to 4: Low risk
  5: Intermediate risk
  6 to 7: High risk
  --------------------------------------------------------------------------------------------------------------------------------------------
